$MYNZ check out the news: Jane Edwards, CCRA, RAC
Post# of 8476
(Total Views: 202)
Posted On: 06/14/2022 9:15:15 AM
$MYNZ check out the news: Jane Edwards, CCRA, RAC brings over 20 years of senior experience developing optimal product and clinical trial strategies in diagnostics and medical devices
Will manage the design and logistical operations of Mainz Biomed’s clinical trials in the US and Europe to support FDA submission
BERKELEY, Calif. and MAINZ, Germany, June 14, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the appointment of Jane Edwards, CCRA, RAC, as VP of Clinical Affairs.
As an integral part of her role, Ms. Edwards will manage the design and logistical operations of the Company’s multifaceted clinical trials - to include subjects in the US and EU - which support key stages of the FDA submission process for ColoAlert, the Company’s highly efficacious, and easy-to-use detection test for colorectal cancer (CRC). She will also develop and liaise closely with Key Opinion Leaders responsible for carrying out, or contributing to, both the European and US clinical studies and supporting related publications.
“The strength of the design and execution of our clinical trials in Europe and the US is integral to the efficiency and effectiveness of our FDA submission and approval process for ColoAlert,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed. “We’re thrilled to welcome Jane to our team and know that having such a highly respected and proven leader in the field of clinical trial strategies in diagnostics and medical devices in charge of our initiatives in this area will ensure that our FDA approval process is as seamless as it can be.”
Ms. Edwards has over 20 years of senior level experience in clinical program strategies including global clinical research and operations, regulatory, technical services and clinical training. She has successfully led clinical operations, and authored and executed studies involving various disease areas including cardiovascular, diabetes, nephrology, toxicology and coagulation. She joins Mainz Biomed from L3 Healthcare, a full-service contract research organization, where, as VP of Clinical Research, she led clinical research and operations.
Will manage the design and logistical operations of Mainz Biomed’s clinical trials in the US and Europe to support FDA submission
BERKELEY, Calif. and MAINZ, Germany, June 14, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the appointment of Jane Edwards, CCRA, RAC, as VP of Clinical Affairs.
As an integral part of her role, Ms. Edwards will manage the design and logistical operations of the Company’s multifaceted clinical trials - to include subjects in the US and EU - which support key stages of the FDA submission process for ColoAlert, the Company’s highly efficacious, and easy-to-use detection test for colorectal cancer (CRC). She will also develop and liaise closely with Key Opinion Leaders responsible for carrying out, or contributing to, both the European and US clinical studies and supporting related publications.
“The strength of the design and execution of our clinical trials in Europe and the US is integral to the efficiency and effectiveness of our FDA submission and approval process for ColoAlert,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed. “We’re thrilled to welcome Jane to our team and know that having such a highly respected and proven leader in the field of clinical trial strategies in diagnostics and medical devices in charge of our initiatives in this area will ensure that our FDA approval process is as seamless as it can be.”
Ms. Edwards has over 20 years of senior level experience in clinical program strategies including global clinical research and operations, regulatory, technical services and clinical training. She has successfully led clinical operations, and authored and executed studies involving various disease areas including cardiovascular, diabetes, nephrology, toxicology and coagulation. She joins Mainz Biomed from L3 Healthcare, a full-service contract research organization, where, as VP of Clinical Research, she led clinical research and operations.
(0)
(0)Scroll down for more posts ▼